Please login to the form below

CAR-T therapy

This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.

FDA hands BMS and bluebird bio a priority review for ide-cel

Myer Squibb and bluebird bio’s submission for their CAR-T immunotherapy ide-cel has finally been accepted by the agency. ... Ide-cel has been awarded a Priority Medicines (PRIME) designation by the European Medicines Agency (EMA), and BMS and bluebird

Latest news

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Sales of its Kite-partnered CAR-T cell therapy Yescarta (axicabtagene ciloleucel) climbed to $156m in the quarter, an increase on the $120m it generated for the same period in 2019.
BMS/bluebird bio resubmit FDA application for myeloma CAR-T

Novel CAR-T therapy targets heavily pre-treated myeloma. Bristol-Myers Squibb and bluebird bio have announced the resubmission of a new biologics license application (BLA) to the US Food and ... BMS/bluebird could face competition from another CAR-T
Gilead and Arcus complete closing of ten-year immunotherapy partnership

It also signed a $2.35bn deal with Nurix for protein degradation drugs for cancer and other diseases, as well as a $11.9bn acquisition of CAR-T cell therapy player
Gilead swoops on Forty Seven with $4.9bn all-cash deal

a run of M&A that hit a peak in 2017 with Gilead’s $11.9bn acquisition of CAR-T cell therapy player Kite Pharma. ... Magrolimab complements our existing work in haematology, adding a non-cell therapy programme that complements Kite’s pipeline of cell
GSK pays $50m upfront to tap Immatics’ cell therapy platform

It’s a similar approach to CAR-T therapy, but according to Immatics TCRs should have broader utility because they can be targeted at proteins inside cancer cells. ... Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’

More from news
Approximately 14 fully matching, plus 89 partially matching documents found.

Latest Intelligence

China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... It now has more than 300 CAR-T clinical trials underway and collaboration with European and
25 Women Leaders in UK Healthcare (part 2)

It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships
Bluebird: on a mission to ‘recode’ the DNA of healthcare

This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma
Cell and gene therapy

In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... In the case of a personalised therapy like CAR-T, the cost of the
Drug launches to watch in 2019

1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH

More from intelligence
Approximately 1 fully matching, plus 21 partially matching documents found.

Latest appointments

Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

In the precision medicine era, the line between products and services is blurred

In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to ... However, due to its novelty, it was difficult to access patients who have
The impossible launch

SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.
The balancing act that’s keeping pharma and biotech market access on its toes

CAR-T cell therapy costs close to $500, 000 per patient in the US, and 300, 000 in Europe. ... Zolgensma, gene therapy for the treatment of spinal muscular atrophy, is (at the time of writing) the most expensive drug in the world at $2.1m.
Understanding the evolving CAR-T market

In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.
Precision paediatrics: Treating patients with CAR-T

Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

Could formulary intelligence be your brand differentiator?: Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
How COVID-19 is accelerating the threat of antimicrobial resistance: Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...